Jennifer Walden, MD, is a graduate of the University of Texas Medical Branch at Galveston. She completed her aesthetic surgery fellowship in New York City at the Manhattan Eye, Ear, and Throat Hospital. She stayed in New York for a number of years where she established a successful plastic surgery practice. She moved back to Austin, Texas in 2011 and founded her current practice, Walden Cosmetic Surgery and Laser Center.
Dr. Jennifer Walden has been in practice for 13 years. She specializes in cosmetic surgery including eyelid lifts, rhinoplasties (nose jobs), face-lifts, liposuction, and breast augmentation. Her profession is mostly made up of men, with only about 850 women in the industry performing as plastic surgeons in comparison with over 7000 men doing the same job. Additionally, when it comes to members of the American Society for Aesthetic Plastic Surgery, there are only 180 women in this leading professional society and just 12 or so in Texas.While being a woman in a male-dominated industry can be very tough, Dr. Walden has turned it into a positive. The vast majority of plastic surgery is performed on women, over 90% in fact.
Many of these women feel a lot more comfortable talking about the work they want performed with another woman like Dr. Walden, especially when it comes to certain parts of their bodies.Dr. Jennifer Walden has talked about why she entered the industry despite the challenges a woman faces in it. She said that early on she learned that, unlike what many people think, having plastic surgery is not an exercise in vanity. Instead, many women have surgery done so that they can feel more confident about themselves and have a better quality of life. She enjoys helping people every day and giving them an appearance that makes their lives just that much better.
For a very a long time, scientists and medical researchers have been scouting for therapeutic alternatives to relapsing-remitting multiple sclerosis (or MS), an autoimmune condition in which the patient’s immune system attacks his or her central nervous system. However, results from a recent clinical trial has rekindled their hopes: it has provided evidence that HDIT (or high-dose immunosuppressive therapy coupled with subsequent autologous hematopoietic cell transplant (or transplantation of the patient’s blood-forming stem cells) could induce long term remission of relapsing-remitting MS.
Because HDIT will be a one-time treatment, it could be more effective than the current long-term treatment options for relapsing-remitting MS patients. The new National Institute of Allergy and Infectious Diseases’ sponsored study findings, therefore, support the development of bigger, randomized trials to compare the effectiveness of HDIT/HCT treatment to the standard care that relapsing-remitting MS patients are currently receiving.
Although an in-depth evaluation of full benefits as well as the potential risk of this treatment option is still needed, the new study results is a great step towards finding sustained remissions of ineffective prognosis of relapsing-emitting MS.
In case the new findings are proved and confirmed in larger studies, HDIT/HCT may become the new therapeutic treatment option for active relapsing-emitting MS patients, especially those who aren’t responding well to existing therapies. This is one of the primary reasons why many medical experts and stakeholders are keenly following the new study and any information related to it. One of these experts is the Voorhees-based Shiva Gopal Vasishta.
Shiva Gopal Vasishta is a practicing Neurologist with over 4 decades of experience. A graduate of the Government Medical College (1979), Dr. Shiva Vasishta is also a psychiatry specialist. Currently, Dr. Shiva Vasishta practices at the prestigious Eastern Neurodiagnostic Associates. He’s also affiliated to Cherry Hill Campus’ Kennedy Health System.